Table 4, Relative risks of clear/nearly clear on IAGI/PGA for all interventions compared to twice daily vehicle/placebo – Sensitvity analysis wherein all data and twice daily combined vitamin D analogue and potent corticosteroid are included - Psoriasis

Intervention	Median RR	Lower Credible Interval	Upper Credible Interval	Probability most effective in SA	Probability most effective in base case
Combined vitamin D and potent corticosteroid BD	5.915	4.820	6.567	45.6	NA
Very potent corticosteroid BD	5.736	4.468	6.549	29.0	48.0
Combined vitamin D and potent corticosteroid OD	5.206	3.667	6.249	3.2	12.7
Very potent corticosteroid OD	4.961	1.526	6.816	18.7	25.3
Potent corticosteroid BD	4.716	3.464	5.736	0.3	2.1
Concurrent vitamin D and potent corticosteroid	4.691	2.677	6.169	2.9	7.9
Vitamin D or vitamin D analogue BD	3.845	2.845	4.789	0.0	0.0
Potent corticosteroid OD	3.560	1.584	5.537	0.1	0.2
Vitamin D or vitamin D analogue OD	3.213	1.655	4.988	0.0	0.0
Dithranol OD	3.018	1.551	4.751	0.0	0.1
Coal Tar BD	2.921	1.303	4.895	0.0	3.6
Tazarotene OD	2.008	0.459	4.936	0.1	0.2
Coal Tar OD	0.852	0.103	3.617	0.0	0.0
Placebo OD	0.729	0.229	1.910	0.0	0.0

From: Appendix K, Network meta-analysis topicals trunk and limbs

Psoriasis: Assessment and Management of Psoriasis.

NICE Clinical Guidelines, No. 153.

National Clinical Guideline Centre (UK).

London: Royal College of Physicians (UK); 2012 Oct.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 4Relative risks of clear/nearly clear on IAGI/PGA for all interventions compared to twice daily vehicle/placebo – Sensitvity analysis wherein all data and twice daily combined vitamin D analogue and potent corticosteroid are included